secwatch.observer — SEC 8-K summary
======================================

Issuer:     IRONWOOD PHARMACEUTICALS INC (IRWD)
CIK:        0001446847
Form:       8-K
Filed at:   2026-05-07T23:59:59+00:00
Accession:  0001104659-26-056656
Event type: earnings
Sentiment:  positive
Materiality: 0.75
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Ironwood Q1 2026: Revenue $107M (+159% YoY); GAAP EPS $0.25 from -$0.23; LINZESS sales $273M (+97%)
--------------------------------------------------------------------------------

- GAAP net income $41M ($0.25 basic EPS) vs loss $37M ($0.23 loss) in Q1 2025.
- LINZESS U.S. net sales $273M, up 97% YoY; 5% EUTRx demand growth.
- Adjusted EBITDA $77M vs negative $4.7M a year ago.
- Maintains full-year 2026 guidance; on track to start apraglutide Phase 3 trial in Q2 2026.
- sNDA for LINZESS in pediatric FC (2-5yrs) accepted with priority review; PDUFA May 24.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1446847/000110465926056656/0001104659-26-056656-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1446847/000110465926056656/tm267094d1_8k.htm
  HTML page:      https://secwatch.observer/filing/0001104659-26-056656

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer